Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers

NCT01462838 is registered in ClinicalTrials.gov with Oryx GmbH & Co. KG as lead sponsor.

NCT NCT01462838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers
Lead sponsor
Oryx GmbH & Co. KG
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2011
Completion date
May 31, 2015
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-induced cancers